Johnson & Johnson: Gastroesophageal Reflux trials

The registry lists 27 Gastroesophageal Reflux studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 4Phase 3 4Phase 4 5No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux DiseaseCompletedNCT02505945Phase 4Results posted
• LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve GastrectomyCompletedNCT02429830Not applicableResults posted
• Early Feasibility Study of the Neovasc Tiara™ Mitral Valve SystemCompletedNCT02276547Not applicableResults posted
• Observational Study of Anti-Reflux SurgeryCompletedNCT01624506Results posted
• An Observational Clinical Feasibility Study of the Magnetic Esophageal SphincterCompletedNCT01058070Not applicableResults posted
• An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux EsophagitisCompletedNCT01008696Phase 4Results posted
• Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)CompletedNCT00992589Phase 3Results posted
• A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric PatientsCompletedNCT00787891Phase 3Results posted
• LINX Reflux Management System Clinical Study ProtocolCompletedNCT00776997Not applicableResults posted
• A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mgCompletedNCT00464308Phase 4Results posted
• RETHINK REFLUX RegistryActive, not recruitingNCT04253392
• Tiara™ Transcatheter Mitral Valve Replacement StudyCompletedNCT03039855Not applicable
• RELIEF Europe StudyTerminatedNCT02762487Not applicable
• A Post-Approval Study of the LINX® Reflux Management SystemCompletedNCT01940185
• Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.CompletedNCT01601379
• A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux DiseaseTerminatedNCT01281553Phase 4
• A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult VolunteersCompletedNCT01101646Phase 1
• Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South KoreaCompletedNCT01018160
• A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)CompletedNCT00855361Phase 1
• A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, InclusiveCompletedNCT00747695Phase 1
• A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, InclusiveCompletedNCT00747526Phase 1
• Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment PeriodCompletedNCT00614536
• Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.CompletedNCT00553449Phase 3
• Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With RabeprazolTerminatedNCT00511966
• Safety of Rabeprazole in Patients Under Multiple TreatmentsTerminatedNCT00511745
• A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)CompletedNCT00236392Phase 3
• A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)CompletedNCT00216489Phase 4